XSHE
002755
Market cap1.83bUSD
Oct 09, Last price
13.34CNY
1D
0.91%
1Q
-9.56%
Jan 2017
-40.95%
IPO
101.30%
Name
Beijing Aosaikang Pharmaceutical Co Ltd
Chart & performance
P/E
52.33
P/S
6.96
EPS
0.25
Div yield, %
0.91%
Shrs. gr., 5y
0.39%
Rev. gr., 5y
-14.00%
Revenues
1.78b
+0.08%
Net income
237m
+47.60%
CFO
652m
+58.41%
Dividend
Jun 18, 20260.12 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating within China, Beijing Aosaikang Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of pharmaceuticals, fine chemicals, and health products. Its diverse offerings include proton pump inhibitor injections, oncology medications, and active pharmaceutical ingredients (APIs), which are applied across key therapeutic areas like digestive disorders, cancer treatment, and infectious diseases. The company was founded in 2003 and is headquartered in Nanjing, China.
Key people
Tao Han
Chief Financial Officer · since 2019
Jingfei Ma
General Manager, Secretary of the Board, Director · since 2022
Xiangfeng Chen
Deputy General Manager, Director · since 2025
Qingcai Chen
Chairman of the Board · since 2022
Xiaowen Wang
Director
Suling Zhou
Director · since 2021
Zaiwei Zong
Director · since 2025
Baisheng Jiang
Independent Director · since 2025
Zhenxing Lin
Independent Director · since 2025
Peiqing Liu
Independent Director · since 2025
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||